Indicaton

Metastatic breast cancer in combination with fulvestrant:

Debio 1347 is an investigational novel orally available small molecule highly selective FGFR 1, 2, 3 ATP competitive inhibitor. Results from the phase 1 clinical trial showed that patients with solid tumors with activating alterations in FGFR may benefit from treatment with Debio 1347. Debio 1347 is expected to become a tailored treatment which will be developed with a companion diagnostic.

Therapeutic indications
Type of product
Table
  • Phase

    Phase II started

  • Partnering status

    Not partnered